Technical Analysis for EQ - Equillium, Inc.
|Grade||Last Price||% Change||Price Change|
EQ closed down 6.99 percent on Thursday, December 13, 2018, on 66 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||N/A||N/A||Down|
|See historical EQ trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 13||New 52 Week Closing Low||Bearish||0.00%|
|Dec 13||Wide Bands||Range Expansion||0.00%|
|Dec 13||Below Lower BB||Weakness||0.00%|
|Dec 13||Lower Bollinger Band Touch||Weakness||0.00%|
|Dec 13||Oversold Stochastic||Weakness||0.00%|
|Dec 12||New 52 Week Closing Low||Bearish||-6.99%|
|Dec 12||Stochastic Reached Oversold||Weakness||-6.99%|
|Dec 12||Wide Bands||Range Expansion||-6.99%|
|Dec 12||Oversold Stochastic||Weakness||-6.99%|
|Dec 11||Wide Bands||Range Expansion||-14.04%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more EQ news...
|52 Week High||19.69|
|52 Week Low||9.21|
|200-Day Moving Average||0.0|
|50-Day Moving Average||0.0|
|20-Day Moving Average||15.4005|
|10-Day Moving Average||14.723|
|Average True Range||2.1086|
|Chandelier Exit (Long, 3 ATRs )||13.3642|
|Chandelier Exit (Short, 3 ATRs )||17.7258|
|Upper Bollinger Band||18.3335|
|Lower Bollinger Band||12.4675|
|Percent B (%b)||-0.02|
|MACD Signal Line||0.0276|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||16.17|
|Resistance 3 (R3)||16.26||15.10||15.53|
|Resistance 2 (R2)||15.10||14.13||15.05||15.32|
|Resistance 1 (R1)||13.73||13.53||13.15||13.64||15.11|
|Support 1 (S1)||11.20||11.60||10.62||11.11||9.63|
|Support 2 (S2)||10.04||11.00||9.99||9.42|
|Support 3 (S3)||8.67||10.04||9.21|
|Support 4 (S4)||8.58|